Investor Presentation

November 06, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, Fort, G Block, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai 400 051 Scrip Code: 506414 Trading Symbol: FERMENTA Dear Sir, Sub.: Intimation of Earnings Presentation – Q2/H1FY27 Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby enclose a copy of Earnings Presentation for Q2/H1FY27 for your information. The said Earnings Presentation will thereafter be uploaded on Company’s website at www.fermentabiotech.com This information is submitted to you pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Kindly take the same on records. Thanking you, Yours faithfully, for FERMENTA BIOTECH LIMITED Varadvinayak Khambete Company Secretary and Head - Legal Membership No. A33861 Encl: As above Fermenta Biotech Ltd Q2/H1FY27 presentation 06 November 2026 Disclaimer By viewing this presentation, the recipient agrees that neither Fermenta Biotech Limited (“FBL”) nor any of its affiliates, directors, officers, employees, or representatives shall be liable for any loss, damage, or liability arising directly or indirectly from the use of or reliance on the information contained herein. The recipient further agrees to indemnify and hold harmless FBL and its representatives from any claims, losses, or damages arising out of or related to any unauthorized use or distribution of this material or any breach of these terms. This presentation may contain forward-looking statements relating to FBL’s future business, financial performance, industry trends, strategy, or objectives. These statements are based on current assumptions and expectations and involve known and unknown risks and uncertainties that may cause actual results to differ materially. Factors such as economic conditions, regulatory changes, market dynamics, technological developments, and global events could impact future outcomes. Forward-looking statements are identified by terms such as “expects” “intends” “may” “believes” “plans” “will” and similar expressions. FBL undertakes no obligation to revise or update these statements. This presentation does not constitute an offer or invitation to buy or sell securities and should not be relied upon for any investment decisions. Investor presentation Q2FY27 2 Innovation Chemistry for Global Nutrition & Wellness As preventive healthcare awareness rises, global demand is accelerating for science-backed, top-quality nutritional ingredients. Fermenta pairs process and molecular expertise with science-validated capability to deliver best-in-class ingredients, trusted by leading brands across the pharmaceutical, dietary supplement, food and beverage, veterinary, and animal nutrition industries. Our edge: decades of global-scale, complex manufacturing and research-driven custom solutions in green chemistry, APIs and intermediates, and environmental solutions. Chemistry built to solve, engineered to scale, and proven in the field by 400+ discerning customers across 60+ countries. Investor presentation Q2FY27 3 Q2/H1FY27 Highlights Financials (consolidated) Performance Q2FY27 H1FY27 • Q2 revenue up 8% on Q1 to INR 135.8 crore, level with Q2FY26; EBITDA up 3% on Q1 INR 135.8 crore INR 261.9 crore Revenue (up 0.1% YoY, up 8% QoQ) (down 7% YoY) • Human Nutrition grew 2% in H1 to INR 162.5 crore, with volumes up 7% over Q1 INR 23.2 crore INR 45.6 crore • India rose to 51% of H1 revenue, from 40% a EBITDA (down 28% YoY, up 3% QoQ) (down 34% YoY) year earlier • Operating cash flow up 44% at INR 54.8 crore; INR 9.4 crore INR 18.9 crore net debt below INR 3 crore Profit after tax (down 48% YoY, down 1% QoQ) (down 52% YoY) • Milestones: VITADEE Green® FSSAI approval (July), NSE listing (August), exclusive VIT Vellore EPS (diluted) INR 3.34 INR 6.67 Vitamin B12 licence (September) • Ahead: VITADEE Green® capacity expected from Q2FY28; Calcifediol expected to be ready for regulatory approvals by end-FY27 Human Nutrition and India carried the half Animal nutrition prices and prior year EBITDA benefiting from insurance income, real estate value unlocking and foreign exchange gains Investor presentation Q2FY27 | 4 Lines of Business Nutrition Primary revenue source focused on nutritional ingredients for health and wellness industries Vitamin D3 - Human Vitamin D3 - Animal Others Premium supplements, food Specialized formulations for Customized Food Premixes, fortification, and pharmaceuticals livestock and poultry feed Fortified Rice Kernels (FRK) and for nutraceutical companies, food applications targeting animal feed Specialized Nutraceutical processors, and pharmaceutical manufacturers, poultry farms, and Ingredients firms dairy producers Others Diversified biotechnology and chemical solutions for industrial and environmental applications API & Intermediates Green Chemistry Environmental Pharmaceutical ingredients and Enzymatic technologies for Biotechnology-based remediation custom synthesis for generic drug eco-friendly processes serving solutions for water treatment and manufacturers and chemical manufacturers, biofuel waste management sectors pharmaceutical developers producers, and cosmetic companies Investor presentation Q2FY27 | 5 Revenue Mix (Consolidated) Human Nutrition rises to 62% of revenue as animal nutrition prices reset (₹ Crore) 9% 5% 6% FY25 FY26 H1FY26 H1FY27 5% 5% 9% 8% 9% Nutrition Business 350 435 220 209 8% 6% 5% 9% Vitamin D3 -Human Nutrition 228 293 159 163 20% 16% 8% Vitamin D3 -Animal Nutrition 82 109 46 22 17% Others 40 33 15 24 Green Chemistry 7 16 4 3 53% 57% Other API & Intermediates 38 48 23 23 Environmental Solutions 22 19 15 17 FY25 FY26 H1FY26 H1FY27 Other Income 20 29 18 11 Vitamin D3 – Human Nutrition Vitamin D3 – Animal Nutrition Value Unlocking Real Estate 45 2 2 0 Nutrition – Others Green Chemistry Total 481 548 281 262 Other API & Intermediates Environmental Solutions Other Income Value Unlocking from Real Estate Human Nutrition grows its share INR 163 crore in H1FY27, up 2% year on year, lifting its share of revenue to 62% from 57% Nutrition Others up 58%; Environmental Solutions up 10% Premixes, fortified rice kernels and specialised ingredients rose to INR 24 crore from INR 15 crore; Environmental Solutions reached INR 17 crore Animal nutrition reflects the price cycle Revenue of INR 22 crore against INR 46 crore, with volumes down 31% and realisations down 35% year on year Investor presentation Q2FY27 | 6 Diversified Markets, Balanced Customers India rises to half of revenue, and customer concentration stays low Customer profile, H1FY27 Geographical revenue mix Excluding value unlocking Revenue from largest customer 9% H1FY27 51% 21% 9% 18% Revenue from top 5 customers 28% Revenue from top 10 customers 43% H1FY26 40% 29% 13% 18% Revenue from India 51% Customers above 5% of revenue 3 FY26 39% 30% 13% 18% Customers at ₹1–5 crore 31 FY25 40% 27% 17% 16% Customers at ₹5–15 crore 11 Customers above ₹15 crore 1 India Europe North America Others India leads: 51% of H1FY27 revenue, from 40% a year earlier, with Europe the second market at 21%. Concentration stays low: the largest customer is 9% of revenue and the top 10 customers together 43%. Customer tiers are measured on half-year revenue, so counts are not comparable with full-year figures. Investor presentation Q2FY27 | 7 Financials H1FY27: Cash Generation Strengthens as Earnings Absorb a Price Reset Income Statement Balance Sheet Cash Flow (₹ Crore) (₹ Crore) (₹ Crore) Total income fell 7% and profit before tax Cash rose 11% to INR 102 crore and debt Operating cash flow rose 44% on a 45%, as animal nutrition prices fell and the eased 4% to INR 105 crore, leaving net debt working-capital release, and free cash H1FY26 base carried one-off other income and below INR 3 crore [Showing first 8,000 characters — download PDF for full document]